Analabs Resources Berhad

KLSE:ANALABS Stok Raporu

Piyasa değeri: RM 188.5m

Analabs Resources Berhad Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Analabs Resources Berhad.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Chemicals kazanç büyümesi18.4%
Gelir büyüme oranın/a
Gelecekteki özkaynak getirisin/a
Analist kapsamı

None

Son güncellemen/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

Jan 04
Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

Analabs Resources Berhad (KLSE:ANALABS) Is Due To Pay A Dividend Of MYR0.02

Feb 13
Analabs Resources Berhad (KLSE:ANALABS) Is Due To Pay A Dividend Of MYR0.02

Analabs Resources Berhad (KLSE:ANALABS) Is Doing The Right Things To Multiply Its Share Price

Mar 28
Analabs Resources Berhad (KLSE:ANALABS) Is Doing The Right Things To Multiply Its Share Price

Analabs Resources Berhad (KLSE:ANALABS) Has A Pretty Healthy Balance Sheet

Jan 21
Analabs Resources Berhad (KLSE:ANALABS) Has A Pretty Healthy Balance Sheet

Here's Why Analabs Resources Berhad (KLSE:ANALABS) Can Manage Its Debt Responsibly

Sep 13
Here's Why Analabs Resources Berhad (KLSE:ANALABS) Can Manage Its Debt Responsibly

Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

May 24
Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

Analabs Resources Berhad (KLSE:ANALABS) Might Be Having Difficulty Using Its Capital Effectively

Apr 28
Analabs Resources Berhad (KLSE:ANALABS) Might Be Having Difficulty Using Its Capital Effectively

Here's Why We Think Analabs Resources Berhad (KLSE:ANALABS) Is Well Worth Watching

Apr 07
Here's Why We Think Analabs Resources Berhad (KLSE:ANALABS) Is Well Worth Watching

Could Analabs Resources Berhad (KLSE:ANALABS) Have The Makings Of Another Dividend Aristocrat?

Mar 17
Could Analabs Resources Berhad (KLSE:ANALABS) Have The Makings Of Another Dividend Aristocrat?

Should You Buy Analabs Resources Berhad (KLSE:ANALABS) For Its Upcoming Dividend?

Feb 19
Should You Buy Analabs Resources Berhad (KLSE:ANALABS) For Its Upcoming Dividend?

Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

Feb 09
Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?

Is Analabs Resources Berhad (KLSE:ANALABS) Set To Make A Turnaround?

Jan 14
Is Analabs Resources Berhad (KLSE:ANALABS) Set To Make A Turnaround?

Is Analabs Resources Berhad (KLSE:ANALABS) An Attractive Dividend Stock?

Dec 07
Is Analabs Resources Berhad (KLSE:ANALABS) An Attractive Dividend Stock?

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Analabs Resources Berhad yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

KLSE:ANALABS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (MYR Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
7/31/2024146292223N/A
4/30/2024152282424N/A
1/31/2024158352830N/A
10/31/2023154332627N/A
7/31/2023145312223N/A
4/30/2023133281516N/A
1/31/2023125121919N/A
10/31/2022123211214N/A
7/31/2022116231315N/A
4/30/2022116291517N/A
1/31/20221202946N/A
10/31/2021119241111N/A
7/31/2021117191011N/A
4/30/2021117161111N/A
1/31/2021108131313N/A
10/31/202010591617N/A
7/31/202010991920N/A
4/30/202011172021N/A
1/31/202010951818N/A
10/31/201911251622N/A
7/31/20191225814N/A
4/30/20191304410N/A
1/31/20191368-65N/A
10/31/201814210-32N/A
7/31/2018136927N/A
4/30/20181389N/A9N/A
1/31/20181459N/A19N/A
10/31/20171449N/A22N/A
7/31/201714811N/A28N/A
4/30/201715011N/A23N/A
1/31/201715812N/A20N/A
10/31/201615513N/A19N/A
7/31/201615814N/A22N/A
4/30/201615513N/A28N/A
1/31/201615112N/A24N/A
10/31/20151539N/A21N/A
7/31/20151437N/A15N/A
4/30/20151427N/A18N/A
1/31/20151356N/A22N/A
10/31/20141368N/A21N/A
7/31/20141408N/A21N/A
4/30/201414010N/A20N/A
1/31/201414611N/A13N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if ANALABS's forecast earnings growth is above the savings rate (3.6%).

Kazançlar ve Piyasa: Insufficient data to determine if ANALABS's earnings are forecast to grow faster than the MY market

Yüksek Büyüme Kazançları: Insufficient data to determine if ANALABS's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if ANALABS's revenue is forecast to grow faster than the MY market.

Yüksek Büyüme Geliri: Insufficient data to determine if ANALABS's revenue is forecast to grow faster than 20% per year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if ANALABS's Return on Equity is forecast to be high in 3 years time


Büyüyen şirketleri keşfedin